Examination of the usefulness of testosterone cream for Late Onset Hypogonadism syndrome

Examination of the usefulness of testosterone cream for Late Onset Hypogonadism syndrome - Examination of the usefulness of testosterone cream for LOHsyndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029540

Enrollment

200

Registered

2017-10-13

Start date

2016-09-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

LOH Syndrome

Interventions

AndroForte2 AndroForte5

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) AMS (Aging Male Symptom Scale) is 27 points or more 2) 12.5 pg / ml or less by free testosterone (RIA method) 3) Male patients aged 20 years or older at the time of consent acquisition 4) After receiving sufficient explanation for the participation of this study, patients who obtained document consent by the patient's free will 5) Outpatient

Exclusion criteria

Exclusion criteria: 1) Cases in which prostate specific antigen exceeds 4.0 ng / mL and the presence of prostate cancer can not be denied. 2) No treatment When the presence of severe sleep apnea syndrome is suspected. (Excluding examples of positive pressure ventilation therapy) 3) When hemoglobin has polycythemia of 18 g / dL or more 4) Cases in which severe cardiovascular lesions are suspected by echocardiography. 5) In addition, patients who are deemed inappropriate as researchers by the research director

Design outcomes

Primary

Measure	Time frame
Amount of change in AMS score at the start of treatment and after 12 weeks	—

Countries

Japan

Contacts

Public ContactShinichi Hisasue

Chibanisi-General Hospital Urology

tiken@chibanishi-hp.or.jp047-384-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026